Growing investments in drug discovery research and development by the pharmaceutical and biotechnology industries, the need for cost-effective screening solutions, the growing emphasis on personalized medicine and precision therapeutics, and the growing demand for novel drug discovery and development are the main factors driving the market.
High Throughput Screening (HTS) is the technique of testing a large number of chemical or biological modulators against predetermined targets.
Download A Sample Brochure : https://meditechinsights.com/high-throughput-screening-market/request-sample/
Increased need for high-throughput screening in drug discovery drives market growth.
High Throughput Screening (HTS) has several uses in drug discovery procedures, acting as a typical tool for discovering lead compounds required for therapeutic development. HTS often uses liquid handling equipment, robotics, plate readers as detectors, and specialized software for instrument control and data processing. While HTS techniques do not directly find medications, their major goal is to quickly locate hit molecules with interesting biological activity. This speeds up the lead discovery process, allowing researchers to quickly identify prospective drug candidates for further optimization and characterization. HTS allows for iterative cycles of compound screening, lead optimization, and structure-activity relationships (SAR), resulting in the production of improved lead compounds with higher potency, selectivity, and drug-like properties. Consequently, the results from HTS assays serve as the starting point for subsequent stages in the drug discovery pipeline, including drug design and understanding the interaction or function of specific biochemical processes.
Advancements in high-throughput screening technologies fuel its demand.
Automation, robotics, and downsizing advancements have greatly improved HTS system throughput and efficiency. Assay downsizing, label-free technologies, and high content screening (HCS) are some of the developing technical advancements that are now being exploited for HTS-led discovery.
The growing adoption of high throughput screening in a variety of applications drives market growth.
High Throughput Screening (HTS) is quickly spreading into new sectors outside traditional drug development. Here are some of its applications:
LAMP-seq test (High-throughput COVID-19 screening): This novel test can simultaneously analyze a large number of swabs using sequencing technology, offering sensitivity similar to the qPCR test.
Proximity Extension Assay: This proteomics test is utilized in Alzheimer’s diagnosis for the high-throughput detection of protein biomarkers in liquid samples.
High-throughput Functional Screening: In the realm of cancer immunotherapy, a highly efficient droplet-based microfluidic platform has been developed. This platform combines a lentivirus transduction system and has demonstrated the ability to screen millions of antibodies to identify potential hits with desired therapeutic functionalities.
Key Constraints of High Throughput Screening Market
The high throughput screening sector confronts several obstacles and limitations. Drug development researchers face ongoing challenges due to high assay prices, apparatus fees, and reagent expenditures. Other restrictions include the complexity of cell-based assays, guaranteeing the diversity and quality of chemical libraries, and ensuring that results are reproducible and reliable across laboratories and platforms.
North America Expected to Continue to Hold a Major Share in the High Throughput Screening Market
From a geographical perspective, North America holds a major market share of the high throughput screening market. This can be mainly attributed to the increasing demand for drug discovery, increasing investments in research and development (R&D) by pharmaceutical companies, and biotechnology firms, technological advancements in high-throughput screening, and open access to high-throughput screening laboratories in the region.
Competitive Landscape Analysis of the High Throughput Screening Market
Some of the key players operating in the market include Agilent Technologies Inc., Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., and Evotec SE, among others.
Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the High Throughput Screening Market
To get a larger market share, players in this market are implementing both organic and inorganic development tactics such as releasing new goods, acquiring related businesses, and forming partnerships. For example,
- Beckman Coulter said in July 2023 that it would launch its hematology analyzer and slidemaker stainer connected to Scopio Labs during the 2023 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo.
- In May 2023, Evotec SE announced the expansion of new high-throughput screening (“HTS”) facilities at their headquarters in Hamburg. This includes more technology for researching the safety and efficacy of novel medicinal candidates.
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
